All Articles
By William King
One-year follow-up data from a phase 3 study found similar duration of response, time to progression (TTP), and survival rates with the biosimilar candidate CT-P16 compared with its reference drug, bevacizumab (Avastin), in the first-line treatment of patients with metastatic or recurrent nonsquamous non–small-cell lung cancer (NSCLC). Read More ›
New results from the PATHFINDER clinical trial suggest that a multicancer early detection blood test can accurately identify the presence of cancer in apparently healthy people. Read More ›
When patients do not have reliable transportation, they cannot receive care for their cancer. Rachel Marquez, BS, MPH, Regional Operations Leader, Galileo Health, New York City, was determined to change this and set up a thriving pilot transportation program at her cancer center, Cone Health. Read More ›
To be compliant and offer the best support to their patients, healthcare providers need to understand the provisions of the Final Rule as it pertains to creating, maintaining, and sharing patient health data, and the impact of this legislation on their practices. Read More ›
Decreasing mortality has been seen since the mid-1990s in patients with multiple myeloma due to intensification of frontline therapies. Read More ›
Single-agent belantamab mafodotin shows anti-myeloma activity in heavily pretreated patients with relapsed/refractory multiple myeloma. Read More ›
Early IONA-MM data show promising real-world evidence of the benefits of isatuximab in patients with relapsed/refractory multiple myeloma. Read More ›
New treatment options are under consideration for consolidation and maintenance therapy after autologous stem-cell transplantation in newly diagnosed patients with multiple myeloma. Read More ›
A single infusion of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma resulted in an overall response rate of 95%. Read More ›
Decades ago, I remember when biosimilars were a light on the horizon. Visions of sharply discounted alternatives to reference brands that could swoop in and help patients receive the care they needed at prices that were at least 50% below current market rates. Read More ›